Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles

International Journal of Clinical and Experimental Pathology

Volumn 6, Issue 9, 2013, Pages 1903-1910

  Lai, Qiaohong ^a   Zhang, Hanwang ^a   Zhu, Guijing ^a   Li, Yufeng ^a   Jin, Lei ^a   He, Long ^a   Zhang, Zhijun ^a   Yang, Ping ^a   Yu, Qilin ^a   Zhang, Shu ^a   Xu, Jun Fa ^b   Wang, Cong Yi ^a,b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Agonist; Antagonist; Assisted reproduction; Controlled ovarian Stimulation cycles; Embryo transfer; Gonadotropin Releasing hormone (GnRH); In vitro fertilization

Indexed keywords

ESTRADIOL; FERTILITY PROMOTING AGENT; FOLLITROPIN; GONADORELIN; HORMONE ANTAGONIST; PROGESTERONE;

ADULT; AGONIST; ANTAGONIST; ARTICLE; ASSISTED REPRODUCTION; BLOOD; COMPARATIVE STUDY; CONTROLLED OVARIAN STIMULATION CYCLES; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EMBRYO TRANSFER; ENDOMETRIUM; FEMALE; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE (GNRH); HUMAN; METABOLISM; METHODOLOGY; NIDATION; OOCYTE RETRIEVAL; OVULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGONIST; ANTAGONIST; ASSISTED REPRODUCTION; CONTROLLED OVARIAN STIMULATION CYCLES; EMBRYO TRANSFER; GONADOTROPIN-RELEASING HORMONE (GNRH); IN VITRO FERTILIZATION;

ADULT; DRUG ADMINISTRATION SCHEDULE; EMBRYO IMPLANTATION; ENDOMETRIUM; ESTRADIOL; FEMALE; FERTILITY AGENTS, FEMALE; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OOCYTE RETRIEVAL; OVULATION; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROGESTERONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84885736037     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Cheung LP, Lam PM, Lok IH, Chiu TT, Yeung SY, Tjer CC and Haines CJ. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005; 20: 616-621.
2. Huirne JA, Homburg R and Lambalk CB. Are GnRH antagonists comparable to agonists for use in IVF? Hum Reprod 2007; 22: 2805-2813.
3. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, Nicollet B, Zorn JR, Bouchard P and Frydman R. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000; 73: 314-320.
4. Sbracia M, Colabianchi J, Giallonardo A, Giannini P, Piscitelli C, Morgia F, Montigiani M and Schimberni M. Cetrorelix protocol versus gonadotropin-releasing hormone analog suppression long protocol for superovulation in intracytoplasmic sperm injection patients older than 40. Fertil Steril 2009; 91: 1842-1847.
5. Bodri D, Sunkara SK and Coomarasamy A. Gonadotropin-releasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2011; 95: 164-169.
6. Itskovitz-Eldor J, Kol S and Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report: short communication. Hum Reprod 2000; 15: 1965-1968.
7. Griesinger G, Felberbaum RE, Schultze-Mosgau A and Diedrich K. Gonadotropin-releasing hormone antagonists for assisted reproductive techniques: are there clinical differences between agents? Drugs 2004; 64: 563-575.
8. Fauser BC and Devroey P. Why is the clinical acceptance of gonadotropin-releasing hormone antagonist cotreatment during ovarian hyperstimulation for in vitro fertilization so slow? Fertil Steril 2005; 83: 1607-1611.
9. Griesinger G, Felberbaum R and Diedrich K. GnRH antagonists in ovarian stimulation: a treatment regimen of clinicians' second choice? Data from the German national IVF registry. Hum Reprod 2005; 20: 2373-2375.
10. Simon C, Oberye J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B and Pellicer A. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod 2005; 20: 3318-3327.
11. Martinez-Conejero JA, Simon C, Pellicer A and Horcajadas JA. Is ovarian stimulation detrimental to the endometrium? Reprod Biomed Online 2007; 15: 45-50.
12. Pu D, Wu J and Liu J. Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. Hum Reprod 2011; 26: 2742-2749.
13. Cota AM, Oliveira JB, Petersen CG, Mauri AL, Massaro FC, Silva LF, Nicoletti A, Cavagna M, Baruffi RL and Franco JG Jr. GnRH agonist versus GnRH antagonist in assisted reproduction cycles: oocyte morphology. Reprod Biol Endocrinol 2012; 10: 33.
14. Papanikolaou EG, Pados G, Grimbizis G, Bili E, Kyriazi L, Polyzos NP, Humaidan P, Tournaye H and Tarlatzis B. GnRH-agonist versus GnRH-antagonist IVF cycles: is the reproductive outcome affected by the incidence of progesterone elevation on the day of HCG triggering? A randomized prospective study. Hum Reprod 2012; 27: 1822-1828.
15. Lai Q, Chen C, Zhang Z, Zhang S, Yu Q, Yang P, Hu J and Wang CY. The significance of antral follicle size prior to stimulation in predicting ovarian response in a multiple dose GnRH antagonist protocol. Int J Clin Exp Pathol 2013; 6: 258-266.
16. Prapas Y, Petousis S, Dagklis T, Panagiotidis Y, Papatheodorou A, Assunta I and Prapas N. GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. Eur J Obstet Gynecol Reprod Biol 2013; 166: 43-46.
17. Krishnamurthy S, Yecole BB and Jussawalla DJ. Uterine cervical adenocarcinomas and squamous carcinomas in Bombay: 1965-1990. J Obstet Gynaecol Res 1997; 23: 521-527.
18. Lavorato HL, Oliveira JB, Petersen CG, Vagnini L, Mauri AL, Cavagna M, Baruffi RL and Franco JG Jr. GnRH agonist versus GnRH antagonist in IVF/ICSI cycles with recombinant LH supplementation: DNA fragmentation and apoptosis in granulosa cells. Eur J Obstet Gynecol Reprod Biol 2012; 165: 61-65.
19. Gilliam ML. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Obstet Gynecol 2011; 118: 706-707.
20. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J and Abou-Setta AM. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011: CD00-1750.
21. Andersen AN. Lack of association between endogenous LH and pregnancy in GnRH antagonist protocols. Reprod Biomed Online 2011; 23: 692-694.
22. Doody K, Devroey P, Gordon K, Witjes H and Mannaerts B. LH concentrations do not correlate with pregnancy in rFSH/GnRH antagonist cycles. Reprod Biomed Online 2010; 20: 565-567.
23. Berin I, Stein DE and Keltz MD. A comparison of gonadotropin-releasing hormone (GnRH) antagonist and GnRH agonist flare protocols for poor responders undergoing in vitro fertilization. Fertil Steril 2010; 93: 360-363.
24. Orvieto R, Homburg R, Meltcer S, Rabinson J, Anteby EY and Scharf S. GnRH agonist versus GnRH antagonist in controlled ovarian hyperstimulation: their role in patients with an unfavorable prognosis a priori. Fertil Steril 2009; 91: 1378-1380.
25. Huang YH, Zhao XJ, Zhang QH and Xin XY. The GnRH antagonist reduces chemotherapy-induced ovarian damage in rats by suppressing the apoptosis. Gynecol Oncol 2009; 112: 409-414.
26. Kim CH, You RM, Kang HJ, Ahn JW, Jeon I, Lee JW, Kim SH, Chae HD and Kang BM. GnRH antagonist multiple dose protocol with oral contraceptive pill pretreatment in poor responders undergoing IVF/ICSI. Clin Exp Reprod Med 2011; 38: 228-233.
27. Andersen AN, Witjes H, Gordon K and Mannaerts B. Predictive factors of ovarian response and clinical outcome after IVF/ICSI following a rFSH/GnRH antagonist protocol with or without oral contraceptive pre-treatment. Hum Reprod 2011; 26: 3413-3423.
28. Out HJ, Rutherford A, Fleming R, Tay CC, Trew G, Ledger W and Cahill D. A randomized, double-blind, multicentre clinical trial comparing starting doses of 150 and 200 IU of recombinant FSH in women treated with the GnRH antagonist ganirelix for assisted reproduction. Hum Reprod 2004; 19: 90-95.
29. Bodri D, Vernaeve V, Guillen JJ, Vidal R, Figueras F and Coll O. Comparison between a GnRH antagonist and a GnRH agonist flare-up protocol in oocyte donors: a randomized clinical trial. Hum Reprod 2006; 21: 2246-2251.
30. Berardelli R, Gianotti L, Karamouzis I, Picu A, Giordano R, D'Angelo V, Zinna D, Lanfranco F, Ghigo E and Arvat E. Effects of cetrorelix, a GnRH-receptor antagonist, on gonadal axis in women with functional hypothalamic amenorrhea. Gynecol Endocrinol 2011; 27: 753-758.
31. Schachter M, Friedler S, Ron-El R, Zimmerman AL, Strassburger D, Bern O and Raziel A. Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective, randomized study. Fertil Steril 2008; 90: 1087-1093.
32. Takahashi K, Mukaida T, Tomiyama T, Goto T and Oka C. GnRH antagonist improved blastocyst quality and pregnancy outcome after multiple failures of IVF/ICSI-ET with a GnRH agonist protocol. J Assist Reprod Genet 2004; 21: 317-322.